Obesity is strongly associated with the development of diabetes mellitus and chronic kidney
disease (CKD), but there is evidence for a bidirectional relationship wherein the kidney also …

BACKGROUND Inhibitors of the Na+-coupled glucose transporter SGLT2 (SGLT2i) primarily
shift the reabsorption of large amounts of glucose from the kidney's early proximal tubule to …

Background: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are recommended
treatment for adults with chronic kidney disease (CKD), but uncertainty exists regarding their …

Obesity is an expanding public health threat that heightens risk of multiple chronic diseases,
including kidney diseases. Within the past two decades, the percentage of US adults with a …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors were initially developed for
their glucose-lowering effects and have shown a modest glycaemic benefit in people with …

Endoplasmic reticulum (ER) is an essential organelle involved in vesicular transport,
calcium handling, protein synthesis and folding, and lipid biosynthesis and metabolism. ER …

Volume overload represents a hallmark clinical feature linked to the development and
progression of heart failure (HF). Alleviating signs and symptoms of volume overload …

What mechanisms can link the inhibition of sodium-glucose cotransporter 2 (SGLT2) in the
early proximal tubule to kidney and heart protection in patients with and without type 2 …

Sodium–glucose cotransporter 2 (SGLT2) inhibitors can cause a reversible decline in
glomerular filtration rate (GFR), which may influence dosing recommendations for renally …

In 2023, there were several new developments in the field of cardionephrology with potential
impact on the care of patients with dual burden of heart and kidney disease. With new drugs …